应用EGFR-TK靶向治疗非小细胞肺癌的临床分析

Clinical analysis of EGFR-TK targeted therapy on non small cell lung cancer

目的分析应用小分子化合物(EGFR-TK)靶向治疗非小细胞肺癌患者的临床效果。方法回顾性分析我院2015年6月至2016年6月收治的46例非小细胞肺癌患者的临床资料,根据双盲法将其分为研究组与对照组。对照组23例非小细胞肺癌患者给予参一胶囊治疗,研究组23例非小细胞肺癌患者给予EGFR-TK靶向治疗,对比两组非小细胞肺癌患者的临床治疗效果和不良反应发生率。结果与对照组相比,研究组患者的不良反应总发生率、疾病控制率明显更优,差异有统计学意义(P<0.05)。结论应用EGFR-TK靶向治疗非小细胞肺癌患者的临床效果十分显著,可以在很大程度上改善非小细胞肺癌患者的临床症状,患者耐受性良好,不良反应轻微,值得在临床治疗工作中推广运用。

Objective To analyze the clinical effect of small molecule compounds （EGFR-TK） targeted treatment for non-small cell lung cancer patients. Methods The clinical data of 46 patients with non-small cell lung cancer admitted in our hospital from June 2015 to June 2016 were retrospectively analyzed, and the patients were divided into research group （23 cases） and control group （23 cases） according to the double blind method. The control group was given Shenyi capsule treatment, while the research group was given EGFR -TK targeted therapy. Then the clinical therapeutic effect and incidence rate of adverse reactions were compared between the two groups. Results In comparison with the control group, the disease control rate and total incidence rate of adverse reactions of the research group were significantly superior, the differences were statistically significant （P〈0.05）. Conclusion Application of EGFR-TK targeted therapy in non-small cell lung cancer is very effective in clinic, it can improve the clinical symptoms of patients with non-small cell lung cancer to a large extent, with good tolerance and mild adverse reactions, which is worthy of promotion in clinical treatment.